This reciprocal resistance underscores the therapeutic rationale for combining CDK4/6 inhibitors with upstream kinase inhibitors tailored to tumor-specific signaling aberrations (Formisano et al., 2019; Heilmann et al., 2014). Here, CDK4 is linked to neoplasm.